ResMed Inc. (NYSE:RMD) Shares Bought by Versant Capital Management Inc

Versant Capital Management Inc increased its holdings in ResMed Inc. (NYSE:RMD - Free Report) by 265.1% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,676 shares of the medical equipment provider's stock after acquiring an additional 1,217 shares during the quarter. Versant Capital Management Inc's holdings in ResMed were worth $375,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Howard Capital Management Inc. raised its holdings in ResMed by 5.3% in the 4th quarter. Howard Capital Management Inc. now owns 900 shares of the medical equipment provider's stock worth $206,000 after purchasing an additional 45 shares in the last quarter. Faithward Advisors LLC raised its stake in ResMed by 4.3% in the fourth quarter. Faithward Advisors LLC now owns 1,279 shares of the medical equipment provider's stock worth $292,000 after buying an additional 53 shares in the last quarter. Meiji Yasuda Life Insurance Co lifted its holdings in ResMed by 4.6% in the fourth quarter. Meiji Yasuda Life Insurance Co now owns 1,356 shares of the medical equipment provider's stock worth $310,000 after buying an additional 60 shares during the period. HighPoint Advisor Group LLC lifted its holdings in ResMed by 2.6% in the fourth quarter. HighPoint Advisor Group LLC now owns 2,570 shares of the medical equipment provider's stock worth $610,000 after buying an additional 64 shares during the period. Finally, ABLE Financial Group LLC boosted its position in ResMed by 2.8% during the 4th quarter. ABLE Financial Group LLC now owns 2,639 shares of the medical equipment provider's stock valued at $604,000 after acquiring an additional 72 shares in the last quarter. Institutional investors own 54.98% of the company's stock.

ResMed Trading Up 0.7%

RMD stock traded up $1.68 during midday trading on Wednesday, reaching $248.73. The company's stock had a trading volume of 147,161 shares, compared to its average volume of 1,008,301. ResMed Inc. has a 1 year low of $179.42 and a 1 year high of $263.05. The firm has a market capitalization of $36.47 billion, a price-to-earnings ratio of 29.37, a PEG ratio of 1.53 and a beta of 0.78. The stock has a fifty day simple moving average of $231.13 and a two-hundred day simple moving average of $234.37. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $2.37 EPS for the quarter, topping the consensus estimate of $2.36 by $0.01. ResMed had a net margin of 25.34% and a return on equity of 26.17%. The company had revenue of $1.29 billion for the quarter, compared to the consensus estimate of $1.28 billion. During the same quarter last year, the firm posted $2.13 EPS. The firm's revenue was up 7.9% compared to the same quarter last year. On average, equities research analysts predict that ResMed Inc. will post 9.47 EPS for the current year.

ResMed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Stockholders of record on Thursday, May 8th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 0.85%. The ex-dividend date is Thursday, May 8th. ResMed's dividend payout ratio is presently 23.79%.

Wall Street Analysts Forecast Growth

RMD has been the topic of a number of recent research reports. Wall Street Zen cut shares of ResMed from a "buy" rating to a "hold" rating in a report on Saturday, May 24th. Morgan Stanley set a $286.00 price objective on shares of ResMed and gave the company an "overweight" rating in a research report on Tuesday, May 20th. Stifel Nicolaus decreased their price target on shares of ResMed from $250.00 to $240.00 and set a "hold" rating on the stock in a research note on Wednesday, March 5th. Royal Bank of Canada increased their target price on ResMed from $247.00 to $255.00 and gave the company a "sector perform" rating in a research report on Thursday, April 24th. Finally, Citigroup upgraded shares of ResMed from a "neutral" rating to a "buy" rating in a research report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, six have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $259.33.

Insider Activity at ResMed

In other ResMed news, insider Kaushik Ghoshal sold 9,745 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $239.31, for a total transaction of $2,332,075.95. Following the completion of the sale, the insider now owns 9,725 shares in the company, valued at $2,327,289.75. This represents a 50.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Witte Jan De sold 2,000 shares of the business's stock in a transaction dated Tuesday, May 20th. The stock was sold at an average price of $243.47, for a total transaction of $486,940.00. Following the completion of the transaction, the director now owns 5,806 shares of the company's stock, valued at $1,413,586.82. This represents a 25.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 39,877 shares of company stock worth $9,231,634. Company insiders own 0.71% of the company's stock.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.